Teva Pharmaceutical Industries
|Headquarters||Petah Tikva, Israel|
|Revenue||$20.3 billion USD (FY 2014)|
|$3.951 billion USD (FY 2014)|
|$3.055 billion USD (FY 2014)|
Number of employees
Teva Pharmaceutical Industries Ltd. (Hebrew: טבע תעשיות פרמצבטיות בע"מ) is an Israeli multinational pharmaceutical company headquartered in Petah Tikva, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and to a lesser extent proprietary pharmaceuticals. It is the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide. Teva's facilities are located in Israel, North America, Europe, and South America. Teva is a member of both the New York Stock Exchange the Tel Aviv Stock Exchange, as well as a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Teva's earliest predecessor was Salomon, Levin, and Elstein Ltd., a wholesale distributor based in Jerusalem that was founded in 1901. During the 1930s, new immigrants from Europe founded several pharmaceutical companies including Teva ("Nature" in Hebrew), Assia, and Zori. In 1951, Teva raised capital through the newly founded Tel-Aviv Stock Exchange.
In 1964, Assia and Zori merged and acquired a controlling interest in Teva. In 1976, these three companies merged into the modern Teva Pharmaceutical Industries Ltd. In 1980, Teva continued to follow its vision of becoming one of the world's biggest pharmaceutical companies by acquiring Ikapharm, then Israel's second largest drug manufacturer.
In 2005, Teva opened a new, state-of-the-art pharmaceutical manufacturing plant in Har Hotzvim, a technology park in Jerusalem. The plant received FDA approval in early 2007. Teva entered the Japanese market in 2005, and in 2008 established a generics joint venture with Kowa.
In 2008, sales totalled $11.08 billion, $13.9 billion in 2009, and in 2010 total sales rose to $16.1 billion, of which a major portion was in Europe and North America. Teva acquired its U.S. rival Ivax Corporation in January 2006, Barr in 2007 and Ratiopharm in 2010.
In 2010, it had 39,660 employees. In Israel, the number of workers rose 7.5% by 6,774. In March 2010, Teva acquired German-based company Ratiopharm in a nearly $5 billion deal, significantly expanding its European coverage. In October 2010, Teva entered a license agreement with BioTime to develop and market BioTime's OpRegen for the treatment of age-related macular degeneration, an effort that in 2013 received $1.5 billion in funding from Israel's Office of the Chief Scientist. In May 2011 Teva announced it will purchase Cephalon for US$6.8 billion as part of its effort to expand its presence in the proprietary pharmaceuticals sector.
Within Teva operates Teva Active Pharmaceutical Ingredients (TAPI) as a stand-alone business unit. On top of supplying a major share of Teva's own needs, the TAPI division is an active competitor in world markets. In 2009, TAPI's sales to third parties totaled $565 million, and in 2010 sales rose by 13% to a total of $641 million.
|Chief Executive Officer||Period of office||Notes|
|Eli Hurvitz||1976 to 2002||CEO & Chairman of the board until his death in 2011.|
|Israel Makov||2002 to 2007|
|Shlomo Yanai||March 2007 to May 2012||Announced his resignation at the beginning of 2012.|
|Jeremy Levin||May 2012 to October 2013|
|Eyal Desheh||October 2013 to January 2014||Interim CEO|
|Erez Vigodman||January 2014 to present day||Desheh returned to previous position of chief financial officer. Vigodman served as the CEO of Makhteshim Agan until joining Teva, and was President and CEO of Strauss Group prior to this. From 2014, Michael Hayden served as Teva's chief scientific officer and president of the company's global research and development.|
Mergers and acquisitions
1980 to 1999
2000 to 2009
In 2000 Teva acquired Canadian based Novopharm. In January 2006, Teva announced completion of its acquisition of IVAX Corporation for approximately $7.4 billion. The acquisition price was $7.4 billion. On December 23, 2008, Teva acquired Barr Pharmaceuticals for $7.5 billion, making Barr and Pliva (which Barr bought earlier) part of Teva.
On March 18, 2010, Teva announced that it planned to acquire German generic Ratiopharm for US$5 billion. The deal was completed in August 2010. In May 2011, Teva bought Cephalon for US$6.8 billion. The same month, Teva announced the ¥40 billion purchase of a majority stake in the Japanese generic drug company Taiyo Pharmaceutical Industry, a move to secure a Japan-local production facility. Teva completed the $934 million acquisition on July 2011. In June 2013 Teva acquired US firm MicroDose for $40 million with as much as $125 million being paid in regulatory and developmental milestones In January 2014, Teva acquired NuPathe after outbidding Endo for $144 million. In June 2014, Teva acquired Labrys Biologics for up to $825 million, the aim being to strengthen the company's migraine pipeline through addition of LBR-101, an anti-CGRP monoclonal antibody therapeutic. In March 2015, Teva acquired Auspex Pharmaceuticals for $3.5 billion growing their CNS portfolio. In April, Teva offered to acquire Mylan for $40 billion, only a fortnight after Mylan offered to acquire Perrigo for $29 billion. Teva's offer for Mylan is contingent on Mylan abandoning its acquisition of Perrigo. Mylan stated in June 2015 that Teva’s disclosure that it had a 1.35 percent stake in Mylan violated US anti-trust rules. In October, the company acquired Mexico-based Representaciones e Investigaciones Medicas (Rimsa) for around $2.3 billion. In the same month Teva acquired Gecko Health Innovations. In November 2015, the company announced it would collaborate with Heptares Therapeutics with its work on small-molecule calcitonin gene-related peptide antagonists for migraine treatment, with the deal generating up to $410 million.
In July 2015, Allergan agreed to sell off its generic drug business (Actavis Generics) to Teva for $40.5 billion ($33.75 billion in cash and $6.75 billion worth of shares). As a result, Teva dropped its pursuit of Mylan. In order for the deal to clear regulatory hurdles, Teva sold off a number of assets - including a portfolio of five generic drugs to Sagent Pharmaceuticals in a deal worth $40 million, as well as a further eight medicines to Dr. Reddy’s in a $350 million deal. Teva also sold a further 15 marketed generics, as well as three others which are close to market, for $586 million to Impax Laboratories. In July, Teva sold off a further 42 products to the Australian generics company - Mayne Pharma for $652 million - the deal will cause Mayne to move up 50 spots into the top-25 companies in the US generic market. As part of the deal Teva will seek to raise $20 to $25 billion through a bond sale.
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
|Teva Pharmaceutical Industries||
Research and development
Teva holds a patent on multiple drugs including: Copaxone, a specialty drug (for the treatment of multiple sclerosis), now the world's best selling MS drug, and Azilect (sold as Agilect in some countries) for treatment of Parkinson's disease. By July 2015 Copaxone held a "31.2 percent shares of total MS prescriptions in the United States." Teva's new 40 mg version of Copaxone taken three times a week "accounted for 68.5 percent of total Copaxone prescriptions in the United States." Copaxone accounts for about fifty percent of "Teva's profit and 20 percent of revenue." Competitors' Glatopa, 20 mg version of Copaxone, is taken once a day.
In June 2006, Teva received from the FDA a 180-day exclusivity period to sell simvastatin (Zocor) in the U.S. as a generic drug in all strengths except 80 mg. Teva presently competes with the maker of brand-name Zocor, Merck & Co.; Ranbaxy Laboratories, which has 180-day exclusivity for the 80 mg strength; and Dr. Reddy's Laboratories, whose authorized generic version (licensed by Merck) is exempt from exclusivity.
In June 2010, the company announced it would discontinue its production of propofol, a major sedative estimated to be used in 75% of all US anesthetic procedures.
- CEP-32496 (renamed RXDX-105) a small molecule inhibitor of BRAF, EGFR and RET, now in Phase I/II trials
- CEP-40783 (renamed RXDX-106) a small molecule inhibitor of AXL and c-Met in preclinical development
- CEP-40125 (renamed RXDX-107) a nanoformulation of a modified bendamustine with potenital activity in solid tumours. Bendamustine Rapid Infusion as therapy for CLL and NHL is part of Teva's specialty drugs pipeline.
- TEV-44229 (renamed RXDX-108) a potent inhibitor of the kinase PKCiota
On June 25, 2010, Bayer sued Teva for falsely claiming that Gianvi, Teva's Generic of Yaz, was "stabilized by betadex as a clathrate." The lawsuit stems from Bayer's US patent, 5798338, on the binding and preservative agents that were not in fact present in Gianvi. "In the preparation of such low-dosed dosage forms, strong fluctuations of the active ingredient concentrations in the dosage units occur almost unavoidably (inadequate content uniformity), which manifest themselves more strongly, the smaller the amount of the active ingredient. It has now been found that the drawbacks that are observed especially in the preparation and storage of dosage forms which contain low-dosed steroidal sex hormones can be avoided, at least to a large extent, if dosage forms are prepared that contain powdery cyclodextrin clathrates of these active ingredients." The settlement of the lawsuit resulted in Teva changing its product marketing to remove the claim that it used the same ingredients as Yaz. Bayer's patent is on a method specifically designed to prevent oxidative degradation of the estrogen.
- Adderall (generic and branded)
- Amikacin Sulfate
- Aripiprazole (generic)
- Augmentin (generic)
- Bisoprolol Fumarate
- Doxorubicin HCl
- Epirubicin HCl
- Epoprostenol Sodium
- Haloperidol Decanoate
- Ibuprofen Max
- Idarubicin HCl
- Leucovorin Calcium
- Montelukast (generic)
- Salbutamol (Albuterol)
- Sulfamethoxazole Trimethoprim
- Economy of Israel
- Science and technology in Israel
- Health care in Israel
- Teva Active Pharmaceutical Ingredients (TAPI)
- "Teva Names a New Chief Executive". Business Day. The New York Times. Bloomberg News. January 2, 2012. Archived from the original on April 27, 2012. Retrieved January 3, 2012.(registration required)
- "TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Israel Company Reports - Search Israeli Companies". www.israelbizreg.com. Retrieved 2016-10-19.
- Hollis, Liz Jones (August 10, 2010). "Teva – Top 10 Generic Drug Companies 2010". FiercePharma. Washington, DC, United States: FierceMarkets. Archived from the original on May 8, 2011. Retrieved November 3, 2010.
- "Teva Pharmaceutical Industries—Jerusalem". Database. Jerusalem, Israel: BioJerusalem. Archived from the original on May 8, 2011.
- http://www.tevapharm.com/about/history.asp The History of Teva
- Singer, Natasha (March 18, 2010). "Teva to Acquire Top German Generics Maker for $5 Billion". The New York Times. Retrieved March 18, 2010.
- Grogan, Kevin (May 5, 2011). "Teva plans $500 million Japan acquisition". PharmaTimes Magazine. London, England. Online PharmaTimes. Archived from the original on May 7, 2011. Retrieved May 7, 2011.
- Jennifer Bayot for the New York Times. July 26, 2005 Teva to Acquire Ivax, Another Maker of Generic Drugs
- Teva Press Release, 2006. Teva Completes Acquisition of Ivax
- Yeshayahou, Koby (February 16, 2011). "Teva employees gain $222m on options". Globes. Rishon Le-Zion, Israel: Globes Publisher Itonut. globes-online.com. Archived from the original on May 8, 2011.
- Jonathan D. Rockoff; Eyk Henning (March 19, 2010). "Teva to Acquire Generics Firm". The Wall Street Journal. New York City. WSJ.com. Archived from the original (~100 words) on May 8, 2011. Retrieved May 8, 2011.
- Robert Daniel; Polya Lesova (March 18, 2010). "Teva to acquire Ratiopharm in deal valued near $5 billion". MarketWatch. New York City: Dow Jones & Co. Archived from the original on May 8, 2011. Retrieved May 8, 2011.
- "Cell Cure Neurosciences Ltd., a Subsidiary of BioTime, Inc. and Hadasit Bio Holdings Ltd., Enters into an Exclusive License Option Agreement with Teva Pharmaceutical Industries Ltd.".
- "BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel's Office of the Chief Scientist".
- "Teva Pharmaceutical Industries Ltd (TEVA.O) Officers". Reuters. Archived from the original on September 29, 2008. Retrieved October 11, 2008.
- Coren, Ora (February 21, 2008). "Most respected managers in market: Tshuva, Dankner, Maor and Hurvitz". Haaretz. Archived from the original on October 20, 2012. Retrieved March 21, 2014.
- Teva Pharmaceuticals Inc. (February 14, 2002). "Teva news release hiring Israel Makov". Retrieved September 28, 2014.
- Golan Hazani. (October 18, 2006). "Ynet reports Israel Makov resignation". Retrieved September 28, 2014.
- "Teva CEO Shlomo Yanai leaving in May, to be replaced by American". Haaretz. Retrieved December 7, 2013.
- "Teva CEO Jeremy Levin steps down". Globes. Retrieved October 30, 2013.
- "Israel's Teva Pharm names Vigodman as CEO". Reuters. January 9, 2014. Archived from the original on January 9, 2014.
- "People". Gen. Eng. Biotechnol. News (paper). 34 (4). February 15, 2014. p. 41.
- George, John (July 21, 2014). "Teva completes deal for second migraine-treatment developer". Philadelphia Business Journal. Retrieved July 21, 2014.
- "Teva — Plantex Limited". tapi.com.
- "TEVA NOVOPHARM — Novopharm Limited becomes Teva Canada Limited". newswire.ca.
- Schmit, Julie (July 26, 2005). "USATODAY.com — Teva Pharmaceuticals to buy Ivax in $7.4 billion deal". usatoday.com.
- "Teva Completes Acquisition of Barr". tevapharm.com.
- Nicholson, Chris V. (May 2, 2011). "Teva to Buy Cephalon for $6.8 Billion". The New York Times.
- Teva completes $934m Taiyo acquisition, Globes, 14 July 11
- David Wainer (June 17, 2013). "Teva Adds MicroDose to Respiratory Business in $165 Million Deal". Bloomberg.com.
- "Teva Outbids Endo, Acquires NuPathe for $144M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper). 34 (4). February 15, 2014. p. 10.
- Staff (June 3, 2014). "Teva Buys Labrys, Growing Pain Franchise in Up to $825M Deal". Genetic Engineering & Biotechnology News. Retrieved July 21, 2014.
- Staff (March 30, 2015). "Teva to Acquire Auspex for $3.5B, Growing CNS Portfolio". GEN News Highlights. Genetic Engineering & Biotechnology News. Retrieved April 21, 2015.
- Staff (April 21, 2015). "Teva Offers to Buy Mylan for $40B". GEN News Highlights. Genetic Engineering & Biotechnology News. Retrieved April 21, 2015.
- Staff (April 8, 2015). "Mylan Offers $28.9B for Perrigo". GEN News Highlights. Genetic Engineering & Biotechnology News. Retrieved April 21, 2015.
- Associated Press (April 21, 2015). "Teva Offers to Buy Mylan in $40.1B Cash-And-Stock Deal". Pharmaceutical Processing. Retrieved April 21, 2015.
- Anjali Rao Koppala (1 June 2015). "Mylan says Teva's stake buy violates U.S. anti-trust rules". Reuters. Retrieved 2 June 2015.
- "Teva beefs up in emerging markets with $2.3B Rimsa buyout - FiercePharma".
- "Teva snaps up Gecko and its 'smart inhaler' to pump up respiratory meds - FiercePharma".
- "Teva, Heptares Launch Up-to-$410M+ Migraine Alliance - GEN News Highlights - GEN".
- "Analyst cuts Allergan generics sales estimates as Teva deal close nears - FiercePharma".
- "Teva to Buy Allergan's Generic Drug Unit". Bloomberg.com. July 27, 2015.
- Cynthia Koons (July 27, 2015). "Teva CEO: $40.5 Billion Allergan Deal is Just the Beginning - Bloomberg Business". Bloomberg.com.
- "Teva Purchasing Allergan's Generics Unit in $40.5B Deal". Bloomberg.com. July 27, 2015.
- Chitra Somayaji (July 27, 2015). "Teva Snaps Up Allergan's Generics Arm, Dumping Mylan". Bloomberg.com.
- "Impax Buys Generic Product Portfolio from Teva, Allergan for $586M - GEN News Highlights - GEN".
- "Teva sells castoffs to Impax for $586M as clock ticks on Allergan deal - FiercePharma".
- "Mayne vaults ahead in U.S. with $652M deal for Teva/Allergan meds - FiercePharma".
- "Teva looks for $20B-plus from bond sale to finance Allergan deal - FiercePharma".
- "Form 6-K".
- "Our Specialty Pipeline". Teva Pharmaceutical Industries. nd. Retrieved 16 October 2015.
- "Teva's MS drug Copaxone has strong second-quarter sales". Reuters. Jerusalem, Israel. July 2015. Retrieved 16 October 2015.
- "Teva won't make more of powerful sedative".
- "GEN — News Highlights:Ignyta Buys Four Cancer Compounds from Teva". GEN.
- Bayer HealthCare Pharmaceuticals Inc. (June 25, 2010). "Bayer Sues Teva and Barr for False Advertising and Patent Infringement in Connection with Teva's Generic Oral Contraceptive Gianvi". Retrieved December 26, 2010.
- Backensfeld; et al. (August 25, 1998). "Solid dosage forms that contain clathrates of 17.alpha.-ethinyl estradiol". Retrieved December 26, 2010.
- Maureen M Cavanaugh, Teva Pharmaceuticals (July 1, 2010). "Microsoft Word – Gianvi Pharmacist Letter – RevD – Final 7-1-10 – web versi..." (PDF). Archived from the original (PDF) on March 14, 2012. Retrieved December 26, 2010.
- "Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.". SCOTUSblog. Retrieved January 27, 2015.
- Mfg. by Watson Pharmaceuticals. See Actavis Acquisition and Watson Name Change, and Allergan, Inc. Acquisition and Actavis, plc Name Change
- DeNoon, D. (August 3, 2012). Generic singulair approved. Retrieved from http://www.webmd.com/asthma/news/20120803/generic-singulair-approved
- "Teva Announces Launch Of Generic Protonix Tablets". tevapharm.com.
|Wikimedia Commons has media related to Teva Pharmaceutical Industries.|
- Teva Pharmaceutical Industries Official website
- Pharmaceutical Executive (PDF)
- "Recent Product Launches, Teva Pharmaceuticals USA". Retrieved February 21, 2008.
- The Economic Times